Anna C. Pavlick, MS, DO, Medical Director
Lisa R. Gaynes, Administrative Director
[1]The CTO is a central office that provides the infrastructure and function for operations of Cancer Clinical Trials at NYU Cancer Institute, an NCI designated Cancer Institution.
CTO personnel are available to both faculty and Industry sponsors to assist throughout the entire lifecycle of a protocol from inception to study closeout. We are the central point of contact who coordinate with Investigational Pharmacy, Laboratory, Nursing, OCT (study contract services), FDA, NCI and other collaborating Academic Institutions.
CTO services include ensuring regulatory compliance, complete IRB services; Protocol and Informed Consent Development; Quality Assurance; Safety monitoring and reporting ; Research Nursing; Data Management; Study Budgeting and Clinical Trials Education for faculty and staff. For Investigators wishing to participate in a Clinical Trial the first step is review by the PRMC (Protocol Review and Monitoring Committee).
Please contact Rachel Kennedy, the PRMC Coordinator who will assist you in initiating the process. Telephone: 212-263-4434 or email: prmc.coordinator@nyumc.org [2]
Download the CTO Org Chart [3]
Click here for the Protocol Review and Monitoring Committee (PRMC) [4]
Click here for the Feasibility Committee [5] (Registered Members Only)
Video: What Public Health and Primary Care Providers Need to Know about Cancer Clinical Trials
Yelena Novik [6], MD, FACP, leads a vital NYS Dept. of Health webcast on the importance of enhancing participation in cancer clinical trials. "What Public Health and Primary Care Providers Need to Know about Cancer Clinical Trials" focuses on issues surrounding recruitment and retention of clinical trial patients with a special emphasis placed on minority recruitment.